Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nautilus Biotechnology (NAUT) Assets (2020 - 2026)

Nautilus Biotechnology has reported Assets over the past 7 years, most recently at $177.8 million for Q1 2026.

  • Quarterly results put Assets at $177.8 million for Q1 2026, down 21.92% from a year ago — trailing twelve months through Mar 2026 was $177.8 million (down 21.92% YoY), and the annual figure for FY2025 was $191.1 million, down 21.27%.
  • Assets reached $177.8 million in Q1 2026 per NAUT's latest filing, down from $191.1 million in the prior quarter.
  • Across five years, Assets topped out at $384.7 million in Q1 2022 and bottomed at $177.8 million in Q1 2026.
  • Median Assets over the past 5 years was $288.6 million (2024), compared with a mean of $284.8 million.
  • The largest annual shift saw Assets skyrocketed 155.6% in 2022 before it dropped 22.64% in 2025.
  • Over 5 years, Assets stood at $350.1 million in 2022, then dropped by 12.71% to $305.6 million in 2023, then decreased by 20.56% to $242.7 million in 2024, then fell by 21.27% to $191.1 million in 2025, then fell by 6.98% to $177.8 million in 2026.
  • Business Quant data shows Assets for NAUT at $177.8 million in Q1 2026, $191.1 million in Q4 2025, and $200.9 million in Q3 2025.